$DMAC
DiaMedica Therapeutics Inc. Stock $dmac

$dmac Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000143774920005906 Filed on March 23, 2020

Income Statement

Concept	2020 Q1	2019	2018 Q4
Revenue	$0.00		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.020M	$3.690M	$380.0K
YoY Change	25.93%	34.67%	-50.0%
% of Gross Profit
Research & Development	$1.349M	$7.900M	$1.740M
YoY Change	-48.25%	74.7%	167.69%
% of Gross Profit
Depreciation & Amortization	$6.000K	$21.00K	$10.00K
YoY Change	0.0%	40.0%
% of Gross Profit
Operating Expenses	$1.349M	$11.59M	$2.120M
YoY Change	-60.57%	59.66%	50.35%
Operating Profit	-$2.404M	-$11.59M
YoY Change	-29.73%	71.47%
Interest Expense		$0.00	-$10.00K
YoY Change		-100.0%	-106.67%
% of Operating Profit
Other Income/Expense, Net	-$12.00K	$975.0K	$180.0K
YoY Change	-93.26%	-11.92%	-28.0%
Pretax Income	-$2.416M	-$10.62M	-$1.960M
YoY Change	-25.5%	87.8%	94.06%
Income Tax	$9.000K	$31.00K	$10.00K
% Of Pretax Income
Net Earnings	-$2.425M	-$10.65M	-$1.960M
YoY Change	-25.43%	85.72%	100.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$185.4K	-$888.2K	-$219.2K
COMMON SHARES
Basic Shares Outstanding	14.14M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.60M	$7.880M	$16.82M
YoY Change	-8.42%	-53.15%	1145.93%
Cash & Equivalents	$3.300M		$16.82M
Short-Term Investments	$9.300M	$4.000M
Other Short-Term Assets	$540.0K	$140.0K	$370.0K
YoY Change	80.0%	-62.16%	516.67%
Inventory
Prepaid Expenses			$369.0K
Receivables	$985.0K		$780.0K
Other Receivables			$0.00
Total Short-Term Assets	$14.17M	$8.840M	$17.97M
YoY Change	-5.21%	-50.81%	1102.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$60.00K	$220.0K	$96.00K
YoY Change	-33.33%	120.0%	159.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$270.0K
YoY Change		-100.0%	0.0%
Total Long-Term Assets	$200.0K	$210.0K	$367.0K
YoY Change	-63.64%	-43.24%	19.16%
TOTAL ASSETS
Total Short-Term Assets	$14.17M	$8.840M	$17.97M
Total Long-Term Assets	$200.0K	$210.0K	$367.0K
Total Assets	$14.37M	$9.050M	$18.34M
YoY Change	-7.29%	-50.65%	917.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$444.0K	$180.0K	$483.0K
YoY Change	-35.18%	-86.05%	-47.5%
Accrued Expenses	$435.0K	$1.130M	$808.0K
YoY Change	-36.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$935.0K	$1.320M	$1.296M
YoY Change	-34.39%	1.54%	29.21%
LONG-TERM LIABILITIES
Long-Term Debt	$10.00K	$10.00K	$20.00K
YoY Change	-50.0%	-50.0%
Other Long-Term Liabilities	$100.0K	$110.0K
YoY Change	-33.33%
Total Long-Term Liabilities	$107.0K	$120.0K	$18.00K
YoY Change	-34.36%	500.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$935.0K	$1.320M	$1.296M
Total Long-Term Liabilities	$107.0K	$120.0K	$18.00K
Total Liabilities	$1.042M	$1.440M	$1.314M
YoY Change	-34.38%	9.92%	31.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$59.04M		-$45.97M
YoY Change	19.96%		14.25%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.32M	$7.620M	$17.03M
YoY Change
Total Liabilities & Shareholders Equity	$14.37M	$9.050M	$18.34M
YoY Change	-7.29%	-50.65%	917.7%

Cashflow Statement

Concept	2020 Q1	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$2.425M	-$10.65M	-$1.960M
YoY Change	-25.43%	85.72%	100.0%
Depreciation, Depletion And Amortization	$6.000K	$21.00K	$10.00K
YoY Change	0.0%	40.0%
Cash From Operating Activities	-$2.978M	-$9.102M	-$1.900M
YoY Change	-4.98%	59.8%	95.88%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$2.000K	$10.00K
YoY Change		-96.0%	-200.0%
Acquisitions
YoY Change
Other Investing Activities	-$5.300M	-$3.910M
YoY Change	-51.51%
Cash From Investing Activities	-$5.301M	-$3.908M	$10.00K
YoY Change	-51.49%	7716.0%	-200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$8.500M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.696M	70.00K	14.82M
YoY Change	-384900.0%	-99.67%	856.13%
NET CHANGE
Cash From Operating Activities	-2.978M	-9.102M	-1.900M
Cash From Investing Activities	-5.301M	-3.908M	10.00K
Cash From Financing Activities	7.696M	70.00K	14.82M
Net Change In Cash	-583.0K	-12.94M	12.93M
YoY Change	-95.85%	-183.65%	2168.42%
FREE CASH FLOW
Cash From Operating Activities	-$2.978M	-$9.102M	-$1.900M
Capital Expenditures	$2.000K	$2.000K	$10.00K
Free Cash Flow	-$2.980M	-$9.104M	-$1.910M
YoY Change	-4.91%	58.44%	98.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001401040
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14139074
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	53400000
CY2019	dei	Security12b Title Security12bTitle	Voting Common Shares, no par value per share
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Trading Symbol TradingSymbol	dmac
CY2019Q4	dmac	Accrued Clinical Study Costs Current AccruedClinicalStudyCostsCurrent	433000
CY2018Q4	dmac	Accrued Clinical Study Costs Current AccruedClinicalStudyCostsCurrent	292000
CY2019	dei	Entity Registrant Name EntityRegistrantName	DiaMedica Therapeutics Inc.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	823000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	780000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1076000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	808000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000
CY2019Q4	dmac	Accrued Research And Professional Fees Current AccruedResearchAndProfessionalFeesCurrent	172000
CY2018Q4	dmac	Accrued Research And Professional Fees Current AccruedResearchAndProfessionalFeesCurrent	65000
CY2019Q4	dmac	Accrued Taxes And Other Liabilities Current AccruedTaxesAndOtherLiabilitiesCurrent	52000
CY2018Q4	dmac	Accrued Taxes And Other Liabilities Current AccruedTaxesAndOtherLiabilitiesCurrent	34000
CY2018	dmac	Adjustments To Additional Paid In Capital Warrants Exercised AdjustmentsToAdditionalPaidInCapitalWarrantsExercised	731000
CY2019Q4	dmac	Deferred Tax Assets Property Patents And Other DeferredTaxAssetsPropertyPatentsAndOther	294000
CY2018Q4	dmac	Deferred Tax Assets Property Patents And Other DeferredTaxAssetsPropertyPatentsAndOther	293000
CY2019Q4	dmac	Deferred Tax Assets Property Share Issue Costs DeferredTaxAssetsPropertyShareIssueCosts	395000
CY2018Q4	dmac	Deferred Tax Assets Property Share Issue Costs DeferredTaxAssetsPropertyShareIssueCosts	529000
CY2019	dmac	Effective Income Tax Rate Reconciliation Income Tax Recovery Amount EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount	-2841000
CY2018	dmac	Effective Income Tax Rate Reconciliation Income Tax Recovery Amount EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount	-1119000
CY2019	dmac	Effective Income Tax Rate Reconciliation Revaluation Of Warrant Liability Amount EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount
CY2018	dmac	Effective Income Tax Rate Reconciliation Revaluation Of Warrant Liability Amount EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount	450000
CY2019	dmac	Income From Governmental Assistance IncomeFromGovernmentalAssistance	856000
CY2018	dmac	Income From Governmental Assistance IncomeFromGovernmentalAssistance	1214000
CY2019	dmac	Noncash Lease Expense NoncashLeaseExpense	49000
CY2018	dmac	Noncash Lease Expense NoncashLeaseExpense
CY2019	dmac	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants
CY2018	dmac	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	5840000
CY2019	dmac	Reclassification Of Warrant Liability Upon Warrant Exercise ReclassificationOfWarrantLiabilityUponWarrantExercise
CY2018	dmac	Reclassification Of Warrant Liability Upon Warrant Exercise ReclassificationOfWarrantLiabilityUponWarrantExercise	123000
CY2019Q4	dmac	Research And Development Incentive Receivable ResearchAndDevelopmentIncentiveReceivable	793000
CY2018Q4	dmac	Research And Development Incentive Receivable ResearchAndDevelopmentIncentiveReceivable	622000
CY2018	dmac	Research Grant Recognized Research Activities Performed2018 ResearchGrantRecognizedResearchActivitiesPerformed2018	621000
CY2019	dmac	Research Grant Recognized Research Activities Performed2019 ResearchGrantRecognizedResearchActivitiesPerformed2019	856000
CY2019Q4	dmac	Rights Exercisable Percent Of Discount To Market Price RightsExercisablePercentOfDiscountToMarketPrice	0.5
CY2019Q4	dmac	Rights Threshold Trigger To Be Exercisable Percent Of Common Stock Outstanding Owned By Individual RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual	0.2
CY2018	dmac	Stock And Warrants Issued During Period Value Common Stock And Warrants StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants	5840000
CY2018	dmac	Stock Issued During Period Shares Exercise Of Common Stock Warrants StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants	128594
CY2018	dmac	Warrants And Rights Exercises In Period WarrantsAndRightsExercisesInPeriod	123000
CY2019Q4	dmac	Working Capital WorkingCapital	7500000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1258000
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1291000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	182000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	483000
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	182000
CY2018Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	483000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64232000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62993000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1164000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	620000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2213495
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1468105
CY2019Q4	us-gaap	Assets Assets	9053000
CY2018Q4	us-gaap	Assets Assets	18339000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	8836000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	17972000
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	217000
CY2018Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	367000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16823000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1353000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3883000
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12940000
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15470000
CY2019Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	7900000
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3598317
CY2019Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2018Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2019	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2018	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12006874
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11956874
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12006874
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11956874
CY2019Q4	us-gaap	Common Stock Value CommonStockValue
CY2018Q4	us-gaap	Common Stock Value CommonStockValue
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10647000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5734000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> financial institutions. These balances generally exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any losses in such accounts and believes it is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</div></div></div>
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	817000
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	887000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12733000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10886000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11211000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9280000
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	3000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	13000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	417000
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y109D
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2100000
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	39000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12733000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10886000
CY2018Q4	us-gaap	Deferred Tax Liabilities Deferred Expense DeferredTaxLiabilitiesDeferredExpense	97000
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	62000
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	45000
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2019Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	88000
CY2018Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent
CY2019Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent
CY2018Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	271000
CY2019	us-gaap	Depreciation Depreciation	21000
CY2018	us-gaap	Depreciation Depreciation	15000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.89
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	419000
CY2019	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired
CY2018	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	24000
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	6000
CY2018Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	5000
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	13000
CY2018Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18000
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5000
CY2018	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3693000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2739000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10618000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5654000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2429000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1131000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	137000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	103000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	315000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	243000
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-9000
CY2018	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	172000
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	26000
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	80000
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	13000
CY2018Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	134000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-301000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-30000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	43000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	700000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	226000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	402000
CY2019	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-183000
CY2018	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-322000
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	308000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	11000
CY2019	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	74000
CY2018	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.09
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	180000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	66000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	46000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	68000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	21000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9053000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18339000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1318000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1296000
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	118000
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18000
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3995000
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21216000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3908000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9102000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5696000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-10649000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-5734000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	975000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1107000
CY2019	us-gaap	Operating Expenses OperatingExpenses	11593000
CY2018	us-gaap	Operating Expenses OperatingExpenses	7261000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-11593000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-6761000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	65000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	159000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	54000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	105000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	153000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	119000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-68000
CY2019Q4	us-gaap	Other Receivables OtherReceivables	17000
CY2018Q4	us-gaap	Other Receivables OtherReceivables	24000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12919000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	47000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	369000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14726000
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	9000000
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	13000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	43000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	75000
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	607000
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	14000
CY2018	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	17000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	107000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	120000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56617000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7900000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4522000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45968000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	500000
CY2019Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	641613
CY2019Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1220359
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	242332
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	578747
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	87472
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	3.94
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.75
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.73
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	918000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1164000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	620000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	75000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	104000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	725825
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.21
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	508000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	301938
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.07
CY2019	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y109D
CY2019Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	5.33
CY2019	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y73D
CY2018	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	620000
CY2019	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1164000
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	16954
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14726000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	43000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	75000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	7617000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	799000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	17025000
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</div></div></div>
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	54000
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	84000
CY2018Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11987696
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7743520

Files In Submission

Name	View Source	Status
0001437749-20-005906-index-headers.html	Edgar Link	pending
0001437749-20-005906-index.html	Edgar Link	pending
0001437749-20-005906.txt	Edgar Link	pending
0001437749-20-005906-xbrl.zip	Edgar Link	pending
dmac-20191231.xml	Edgar Link	completed
dmac-20191231.xsd	Edgar Link	pending
dmac-20191231_cal.xml	Edgar Link	unprocessable
dmac-20191231_def.xml	Edgar Link	unprocessable
dmac-20191231_lab.xml	Edgar Link	unprocessable
dmac-20191231_pre.xml	Edgar Link	unprocessable
dmtp20191231_10k.htm	Edgar Link	pending
ex_178133.htm	Edgar Link	pending
ex_178134.htm	Edgar Link	pending
ex_178135.htm	Edgar Link	pending
ex_178136.htm	Edgar Link	pending
ex_178137.htm	Edgar Link	pending
ex_178138.htm	Edgar Link	pending
ex_178139.htm	Edgar Link	pending
ex_178140.htm	Edgar Link	pending
ex_178141.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
graph01.jpg	Edgar Link	pending
graph02.jpg	Edgar Link	pending
graph03.jpg	Edgar Link	pending
graph04.jpg	Edgar Link	pending
graph05.jpg	Edgar Link	pending
picture01.jpg	Edgar Link	pending
picture02.jpg	Edgar Link	pending
picture03.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
table01.jpg	Edgar Link	pending
table02.jpg	Edgar Link	pending
table03.jpg	Edgar Link	pending
table04.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DMAC
DiaMedica Therapeutics Inc. Stock $dmac

2020 Q1 Form 10-K Financial Statement

#000143774920005906 Filed on March 23, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMAC DiaMedica Therapeutics Inc. Stock $dmac

2020 Q1 Form 10-K Financial Statement

#000143774920005906 Filed on March 23, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMAC
DiaMedica Therapeutics Inc. Stock $dmac